Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-27
2005-12-27
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S077000, C514S091000, C514S218000
Reexamination Certificate
active
06979682
ABSTRACT:
A novel use of platelet-activating factor antagonists that bind to intracellular PAF binding sites such as BN-50730 (tetrahedra-4,7,8,10 methyl-1 (chloro-1 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4′,3′-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4) has been discovered. These intracellular-binding platelet-activating factor antagonists were found to inhibit both in vivo and in vitro tumor growth and angiogenesis where the angiogenesis is stimulated by basic fibroblast growth factor.
REFERENCES:
patent: 01/83440 (2001-08-01), None
Hunt, J. D. et al., “The Platelet-Activationg Factor (FAF) Antagonist BN-50730 Inhibits Antgiogenesis,” Proceedings of the American Association for Cancer Research: Cell and Tumor Biology, vol. 41, abstract 4099, (2000).
Angelov, L. et al., “Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas,” Cancer Research, vol. 59, pp. 5536-5541 (1999).
Bazan, N.G. et al., “Platelet-activating factor and retinoic acid synergistically activate the inducible prostaglandin synthase gene,” Proc.Natl.Acad.Sci.USA, vol. 91, pp. 5252-5256 (1994).
Bicknell, R., “Vascular targeting and the inhibition of angiogenesis,” Annals of Oncology, vol. 5, pp. 45-50 (1994)
Camussi, G. et al., “Angiogenesis induced in vivo by hepatocyte growth factor is mediated by platelet-activating factor stnthesis from macrophages,” J. Immunol., vol. 158, pp. 1302-1309. (1997).
Flaumenhaft, R. et al., “Role od extracellular matrix in the action of basic fibroblast growth factor: Matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis,” Journal of Cellular Physiology, vol. 140, pp. 75-81 (1989).
Friesel, R.E. et al., “Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction,” FASEB Journal, vol. 9, pp. 919-925 (1995).
Hunt, J.D. et al., “A Platelet-Activating Factor Antagonist, BN-50730, Inhibits Basic Fibroblast Growth Factor-Induced Human Umbilical Vein Endothelial Cell Proliferation and Tumor Xenograft Expansion in Athymic Nude Mice,” submitted to Cancer, on Sep. 27, 2000.
Hunt, J.D. et al., “The Platelet-Activating Factor (PAF) Antagonist BN-50730 Inhibits Angiogenesis,” Proceedings of the American Association for Cancer Research: Cell and Tumor Biology, vol. 41, abstract 4099 (2000).
Jaye, M. et al., “Human endothelial cell growth factor: cloning, nucleotide sequence, and chromosome localization, ” Science, vol. 233, pp. 541-546 (1986).
Lee. P.L. et al., “Purification and complementary DNA cloning of a receptor for basic fibroblast growth factor,” Science, vol. 245, pp. 57-60 (1989).
Marchesell, V.L.L. and N.G. Bazan, “Platelet-activating factor is a messenger in the electroconvulsive shock-induced transcriptional activation of cfosandzif-268 in hippocampus,” Journal of Neuroscience Research, vol. 37, pp. 54-61 (1994).
Marcheselli, V.L. et al., “Distinct platelet-activating factor binding sites in synaptic endings and intracellular membranes of rat cerebral cortex,”Journal of Biological Chemistry, vol. 265, pp. 9140-9145 (1990).
Montrucchio, G. et al., “Nitric oxide mediates angiogenesis induced invivoby platelet-activating factor and tumor necrosis factor-α,” American Journal of Pathology, vol. 151, pp. 557-563 (1997).
Montrucchio, G. et al., “Tumor necrosis factor α-induced angiogenesis depends on in situ platelet-activating factor biosynthesis,” J. Exp. Med., vol. 180, pp. 377-382 (1994).
Pires, A.L.A. et al., “Long-lasting inhibitory activity of the hetrazepinic BN-50730 on exudation and cellualr alterations evokedby PAF and LPS,” Br.J.Pharmacol., vol. 113, pp. 994-1000 (1994).
Silva, C.L. et al., “Formation of highly stable complex between BN-50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4'3'-4,5]thieno [3,2-f]triazolo-1,2,4 [4,3-a]diazepine-1,4]and the platelet-activating factor receptor in rabbit platelet membranes,” Biochemical Pharmacology, vol. 51, pp. 193-196 (1996).
Bazan Haydee E.
Bazan Nicholas G.
Gomez Julio Alvarez Builla
Hunt Jay D.
Marcheselli Victor L.
Board of Supervisors of Louisiana State University and Agricultu
Davis Bonnie J.
Jones Dwayne
Runnels John H.
LandOfFree
Platelet-activating factor antagonist inhibition of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Platelet-activating factor antagonist inhibition of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Platelet-activating factor antagonist inhibition of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3493328